Voices: Emil Ciurczak
The plenary session early Monday set the overall tone of the conference: “We’re growing because we address what will be happening in pharma, not merely what was done previously,” said Tim Stevens, associate director, Bristol-Myers Squibb, pointing out that while most professional meetings were shrinking, IFPAC was growing, largely due to the agency presence and access to upper echelons of FDA personnel. The thrust of the meeting was the future of pharma — which will clearly be dominated by continuous manufacturing (CM).Read More
More from this voice...
- Sep 1, 2016Packaging does much more than serve as a place for the label
- Sep 8, 2014Pharma’s still skeptical about PAT’s true efficacy. But continuous processing may moot the argument.
- Jun 5, 2014U.S. regulators want more than release tests to prove biosimilar safety and efficacy
- Mar 28, 2014Continuous manufacturing’s rising star has process analytical technologies at its heart.
- Sep 18, 2013PAT-based analysis methodologies help see, quality and quantify subtle changes in dosage forms
- May 29, 2013Q&A with Dr E. Neil Lewis, Chief Technology Officer, Malvern Instruments
- Apr 23, 2013Either true or simulated, moving bed chromatography has real potential to speed the flow downstream